Financing Round Co-led by Catalys Pacific and
SR One, Investment to Drive the Development of Sparsentan
for IgA Nephropathy in Japan
and Other Asian Countries
TOKYO, July 17,
2024 /PRNewswire/ -- Renalys Pharma, Inc., a
late-stage clinical biopharmaceutical company has completed a
¥6.0Bn Series A financing. The financing was led by Catalys
Pacific and SR One, along with additional investors, including JPS
Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank
Co., Ltd., Japan Co-Invest IV Limited Partnership, NVCC NO.9
Investment Limited Partnership.
The Series A financing will enable Renalys Pharma to complete
its Phase III clinical trial for sparsentan, a promising treatment
for IgA nephropathy, in Japan.
IgA nephropathy is a prevalent kidney disease in Japan and throughout Asia. Renalys Pharma obtained the rights
to sparsentan through a licensing agreement with Travere
Therapeutics, Inc. In April
2024, Renalys Pharma submitted an Investigational New Drug
(IND) Application for sparsentan to the Pharmaceuticals and Medical
Devices Agency (PMDA) in Japan and
plans to initiate an open-label registrational study in Q2 2024,
with anticipated results from the urine protein/creatinine ratio
endpoint in the second half of 2025. This Phase III
registration study will bring Renalys Pharma closer to providing a
much-needed treatment option for patients living with IgA
nephropathy across the region.
"Renalys is committed to developing innovative treatments that
address growing healthcare inequities for patients in Japan and Asia," said BT Slingsby, founding CEO of
Renalys Pharma and Founder and Managing Director of Catalys
Pacific. "At Renalys, our paramount objective is to introduce new
medicines that transform clinical medicine and patients' lives,
beginning with sparsentan for IgA nephropathy."
"SR One is proud to actively partner with entrepreneurs,
offering our full support to build transformative biotechnology
companies," said Rajeev Dadoo, PhD,
Managing Partner of SR One. "We are thrilled to join forces with
Renalys as they push forward their pipeline of what we believe to
be innovative renal disease therapies. Our investment in Renalys
reflects our confidence in their ability to develop much-needed new
medicines for patients in Japan
and across Asia."
About Renalys Pharma, Inc.
Renalys Pharma, a privately
held late-stage clinical biopharmaceutical company based in
Japan, is committed to the
development of multiple innovative therapeutics targeting unmet
needs in the management of renal disease for Japanese and Asian
patients. Founded by Catalys Pacific and SR One in 2023, the
company aims to address the growing problem of "drug loss" by
catalyzing access to new treatments for kidney disease patients in
Japan and other Asian regions. To
learn more about Renalys Pharma, please visit
https://renalys.com/.
About Catalys Pacific
Catalys Pacific is a
transpacific life sciences investment firm that provides solutions
for patients worldwide through the creation of investments in
biopharma companies. Catalys Pacific is led by a team of
entrepreneurs and investors who work closely with partners in
academia, venture capital, and the pharmaceutical industry. The
firm maintains offices in Japan
and the West Coast of the US. For more information, visit
catalyspacific.com.
About SR One
SR One is a transatlantic
biotechnology investment firm that collaborates with entrepreneurs
and investment partners in an effort to build elite
biotechnology companies. SR One's mission is to translate
innovative technologies and scientific discoveries into
next-generation medicines with the potential to benefit patients
with significant unmet medical needs. For more information,
visit www.srone.com.
Disclaimer
Information concerning pharmaceutical
products (compound under development) contained herein is not
intended as advertising or medical advice but intended for
disclosure of management information.
View original
content:https://www.prnewswire.com/news-releases/renalys-pharma-closes-6-0bn-series-a-financing-to-advance-kidney-disease-treatments-across-asia-302197586.html
SOURCE Renalys